8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 5, 2005

SCHERING—PLOUGH CORPORATION
(Exact Name of Registrant as Specified in its Charter)

New Jersey
(State or Other Jurisdiction of
Incorporation) 1-6571
(Commission File Number) 22-1918501
(IRS Employer
Identification Number)

2000 Galloping Hill Road
Kenilworth, NJ 07033
(Address of Principal Executive Office)

Registrant’s telephone number, including area code: (908) 298-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

	Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
	Item 9.01 Financial Statements and Exhibits.
SIGNATURES
	Exhibit Index
EX-99.1: PRESS RELEASE

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Effective December 5, 2005, the Board of Directors of Schering-Plough Corporation elected C. Robert Kidder as a member of the Board of Directors. Mr. Kidder was appointed to the Compensation and Finance Committees.

A press release dated December 5, 2005 related to Mr. Kidder’s appointment is attached as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

EXHIBIT NO.	DESCRIPTION
99.1	Press Release, dated December 5, 2005, entitled “Schering-Plough Elects C. Robert Kidder to Board of Directors.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Schering-Plough Corporation

By:/s/ Susan Ellen Wolf

Susan Ellen Wolf
Corporate Secretary, Vice President, Corporate Governance
and Associate General Counsel

Date: December 5, 2005

Exhibit Index

Exhibit No.	Description
99.1	Press Release, dated December 5, 2005, entitled “Schering-Plough Elects C. Robert Kidder to Board of Directors.”

EX-99.1

Exhibit 99.1

News Release

Schering-Plough Corporation
2000 Galloping Hill Road
Kenilworth, New Jersey 07033-0530

FOR RELEASE: IMMEDIATELY	Media Contact:	Denise Foy
		(908) 298-7616
	Investor Contacts:	Alex Kelly
		(908) 298-7436

SCHERING-PLOUGH ELECTS C. ROBERT KIDDER TO BOARD OF DIRECTORS

     KENILWORTH, N.J., Dec. 5, 2005 — Schering-Plough Corporation (NYSE: SGP) today announced the election of C. Robert Kidder as a member of its Board of Directors. Kidder is an independent director under both the New York Stock Exchange standards and the more restrictive Schering-Plough Board independence standard. Kidder is a principal of Stonehenge Partners, Inc. (a private investment firm) and retired Chairman and CEO of Borden Chemical, Inc.

     “Bob brings broad experience in the management of complex global organizations and sophisticated financial transactions,” said Fred Hassan, Schering-Plough chairman and chief executive officer. “His experience and good judgment will be important as we move forward with new phases of our Action Agenda to transform Schering-Plough into a high-performance, global competitor.”

     Kidder is also a director of Electronic Data Systems Corp. and Morgan Stanley (and its predecessor company Dean Witter). He is active in community service activities and serves on the Board of Trustees of the Children’s Hospital of Columbus (Ohio), the Wexner Center for the Arts and Ohio University.

     Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough’s vision is to earn the trust of the physicians, patients and customers served by its 30,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

# # #